RIALTO

Trial Overview

RIAltO: A Randomised Investigation of Alternative Ofatumumabcontaining regimens in less fit patients with CLL

Inclusion criteria

  1. CLL requiring treatment by NCI/IWCLL 2008 criteria. At least one of the following criteria:
    1. Progressive marrow failure as manifested by the development of, or worsening of, anaemia and/or thrombocytopenia.
    2.  Massive (i.e. 6 cm below the left costal margin) or progressive or symptomatic splenomegaly.
    3. Massive (i.e. 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
    4. Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months.
  2. No prior therapy for CLL
  3. Full-dose R-FC considered inappropriate for at least one of the following reasons
    1. Age 75 or greater
    2. WHO performance status 2 or 3
    3. Cardiac impairment (NYHA class II)
    4. Respiratory impairment (bronchiectasis or moderate COPD)
    5. Renal impairment (estimated Glomerular Filtration Rate (eGFR) 10-30 ml/min)
    6. Any other significant co-morbidity or factor that makes R-FC inappropriate
  4. Considered able to tolerate Chl at the dose used in the LRF CLL4 trial (10mg/m2 d1-7)
  5. Written informed consent

Exclusion criteria

  1. Neutrophil count less than 1.0 x 109/l or platelet count less than 50 x 109/l unless due to CLL*
  2. Uncontrolled auto-immune haemolytic anaemia or thrombocytopenia
  3. Active infection
  4. Seropositivity for HIV, HCV or HBV (surface antigen or core antibody)
  5. Severe renal impairment (eGFR less than 10ml/min)
  6. Severe hepatic impairment (serum bilirubin more than twice the upper limit of normal) unless due to CLL or Gilbert’s syndrome.
  7. Concurrent treatment with glucocorticoids equivalent to more than prednisolone 20mg od
  8. Prior treatment with monoclonal antibody therapy within the last 3 months.
  9. Yellow fever vaccination within 4 weeks prior to treatment start
  10. Known hypersensitivity to ofatumumab, bendamustine or chlorambucil or any of their excipients
  11. CNS involvement with CLL
  12. History of Richter transformation
  13. Concomitant malignancies within the last 3 years except successfully treated non-melanoma skin cancer or carcinoma in situ.
  14. Major surgery within 28 days prior to randomisation
  15. WHO performance status 4
  16. Severe cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (NYHA III-IV), and arrhythmia (excluding extra systoles or minor conduction abnormalities) unless controlled by therapy.
  17. Any serious underlying medical or psychological conditions, which could impair the ability of the patient to participate in the trial or compromise ability to give informed consent
  18. Treatment within a clinical trial within 30 days prior to trial entry.
  19. Adult patient under tutelage (not competent to sign informed consent).
  20. Pregnant or lactating women.

Consultant Haematologist

Peter Hillmen

Tel: 0113 2068513

E-mail: peter.hillmen@leedsth.nhs.uk

Specialist Nurse

David Buchanan

Tel: 0113 2067436

E-mail: david.buchanan@leedsth.nhs.uk

Other trials currently active for Chronic Lymphocytic Leukaemia

book icon

Gilead 133

A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

book icon

GALACTIC

GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL

book icon

COSMIC

Combination FC plus Ofatumumab at Standard or Mega dose In CLL

book icon

CLL210 (OfaDexRev)

A Phase II Trial of Ofatumumab, Dexamethasone and Lenalidomide Followed by Randomisation to Lenalidomide Maintenance Versus No Further Treatment for High-Risk CLL.

book icon

CLL Lenalidomide Maintanence 002 – The Continuum Trial

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA FOLLOWING SECOND-LINE THERAPY (The Continuum Trial)

Tags